Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Bortezomib Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma

NCT01517724 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT01517724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01517724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Bortezomib Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
January 24, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma